MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies

K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara (Tokyo, Japan)

Meeting: 2016 International Congress

Abstract Number: 1873

Keywords: Behavioral abnormalities, Dopamine agonists, Excessive daytime sleepiness(EDS), Executive functions

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: This study aimed to demonstrate effectivity and safety of rotigotine transdermal patch (RTP) on motor and cognitive dysfunctions in patients with Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB).

Background: Utility of dopamine agonists (DAs) for PDD/DLB patients and their effects on cognitive dysfunction have not been elucidated because the previous RCTs of DAs have excluded demented patients. Daytime sleepiness and behavioral/psychological symptoms of dementia (BPSD) occur frequently and discourage use of DAs in PDD/DLB. A new non-ergot DA, rotigotine, has a similar receptor affinity profile to that of ergot DAs which induce daytime sleepiness less frequently than non-ergot DAs. Rotigotine is applied once daily using a transdermal patch, providing continuous drug delivery and stable drug concentration for 24 hours, and is generally safe and well tolerated in PD patients. RECOVER study (Trenkwalder C, et al., 2011) has demonstrated that RTP improves both early-morning motor function and nocturnal sleep disturbances in PD patients.

Methods: An open-label study. The subjects were patients with PDD/DLB with parkinsonism who needed improvement in motor dysfunctions. Primary outcomes which are cognitive functions by MMSE, MoCA, and ADAS-cog, BPSD by NPI-Q, and daytime sleepiness by Epworth Sleepiness Scale (ESS), were examined before and after RTP treatment.

Results: The subjects (n=6, age 79±5, H&Y 3.5±1.1; M±SD) were treated with RTP 4-6 mg / 24 hours for 60±42 days. Motor improvement occurred in 67% of the subjects. Total scores of MMSE (18.8±3.6 at baseline), MoCA (12.0±4.4), ADAS-cog (20.1±8.6), NPI-Q (severity 4.5±4.7, caregiver distress 5.3±6.6) and ESS (8.0±2.5) did not change after RTP (19.0±3.5, 12.5±3.8, 19.8±8.9, 4.5±4.8, 4.0±5.3, 11.7±3.7, respectively). Executive function by MoCA tended to improve after RTP (from 0.5±0.8 to 1.3±0.5, p=0.06). Scores of the other 5 cognitive domains by MoCA did not change after RTP.

Conclusions: A new non-ergot DA, RTP, is effective in improving motor symptoms in PDD/DLB patients without worsening dysfunctions in any cognitive domains, BPSD or daytime sleepiness. RTP may improve executive function of PDD/DLB patients which is related to dopamine deficiency in the brain.

To cite this abstract in AMA style:

K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara. Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/effectivity-and-safety-of-rotigotine-transdermal-patch-on-motor-and-cognitive-dysfunctions-in-parkinsons-disease-with-dementia-and-dementia-with-lewy-bodies/. Accessed May 16, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/effectivity-and-safety-of-rotigotine-transdermal-patch-on-motor-and-cognitive-dysfunctions-in-parkinsons-disease-with-dementia-and-dementia-with-lewy-bodies/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley